Tessa Therapeutics Announces New Executive Leadership
Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive…
Continue Reading
-
-
-
-
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by…
Continue Reading -
Technician, Engineering & Facilities (Utilities & HVAC)
Excerpt Publication 2 Sample Excerpt
Continue Reading -
-
Interview Series | In Pursuit of A Cancer Cure: Conversations with Immunotherapy Advocates – Dr Ramy Ibrahim, CMO at PICI
Our CSO, Dr John Connolly, discusses the next decade of cellular immunotherapy breakthroughs with Dr…
Continue Reading -
Senior Analyst/ Analyst, Computer System Validation
Excerpt Publication 2 Sample Excerpt
Continue Reading -
Director/ Senior Director, Regulatory Affairs (New Jersey)
Excerpt Publication 2 Sample Excerpt
Continue Reading -
Tessa Therapeutics, in collaboration with our research partners, presented two sets of results at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Tessa’s CMO, Dr Han Chong Toh, together with Dr Timothy Shuen, first author and presenter…
Continue Reading